Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Rheumatoid Arthritis Drugs Market Valued at Present and by 2029?

In recent times, the market size for rheumatoid arthritis medications has seen a slight downfall. The market which is expected to be $60.3 billion in 2024, is projected to decrease to $60.1 billion in 2025 with a compound annual growth rate (CAGR) of -0.3%. The earlier growth seen in this market was due to an increase in the prevalence of the disease, expansion of healthcare infrastructures, heightened awareness and education efforts, governmental support and initiatives, as well as strategic collaborations.

Predicted growth in the rheumatoid arthritis drugs market signifies a stable advancement in the next couple of years. The expected increase is up to $65.34 billion by 2029, with a compound annual growth rate (CAGR) of 2.1%. The surge in the forecast period is due to the influence of personalized medicine trends, the progression of emerging markets, pipeline development, emphasis on combination treatments, and heightened healthcare expenditure. The most prominent trends expected during the forecast period include the prevalence of biological therapies, the impact of biosimilars, advancements in personalized medicine, the amplification of oral therapies, and an emphasis on early diagnosis and intercession.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10120&type=smp

#What Drivers Are Influencing Growth In The Rheumatoid Arthritis Drugs Market?

The escalating rate of arthritis is predicted to stimulate the development of the rheumatoid arthritis drugs market in the future. Rheumatoid arthritis is an autoimmune and inflammatory disorder in which the immune system intentionally damages healthy cells, resulting in inflammation in the impacted areas of the body. Remedies for rheumatoid arthritis, including drugs and self-management methods, are easily accessible. These drugs reduce pain, improve joint mobility, and prevent the disease from progressing. The National Center for Health Statistics, a US government agency, reported in February 2024 that the age-adjusted prevalence of diagnosed arthritis in adults was 18.9% in 2022, with a larger proportion of women (21.5%) being affected than men (16.1%). The occurrence significantly increased with age, from 3.6% among adults aged 18–34 to 53.9% amongst those who were 75 and older. As a result, the rising number of arthritis cases is expected to fuel the rheumatoid arthritis drugs market.

What Are The Main Segments Identified In The Rheumatoid Arthritis Drugs Market Research?

The rheumatoid arthritis drugs market covered in this report is segmented –

1) By Drug Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Disease-Modifying Antirheumatic Drugs (DMARDs), Biologic Response Modifiers (BRMs), Other Drug Types

2) By Route Of Administration: Oral, Parenteral, Topical, Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Diclofenac, Indomethacin

2) By Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone

3) By Disease-Modifying Antirheumatic Drugs: Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide

4) By Biologic Response Modifiers: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, B-cell Inhibitors

5) By Other Drug Types: Janus Kinase Inhibitors, Other Novel Therapies

What Are The Leading Trends And Opportunities In The Rheumatoid Arthritis Drugs Sector?

The rise of product innovation is a critical trend being observed in the Remicade biosimilar market. Leading corporations in this market are committing to the production of inventive products to maintain their market standing. A case in point is the introduction of Amjevita, a biosimilar to AbbVie’s Humira, by Amgen Inc., a biotechnology firm based in the United States, in January 2023. Amjevita aims to match the original drug in terms of safety and effectiveness and poses as the first biosimilar to Humira, setting it up as a rival for market capital. This biological medication, under use for a range of autoimmune diseases such as rheumatoid arthritis and Crohn’s disease, competes with one of the world’s most costly drugs that generate billions in annual returns for AbbVie. However, Amjevita is projected to be considerably more affordable. Beyond monetary savings, Amjevita also has the potential to provide patients with a greater variety of treatment choices.

Which Companies Play A Key Role In The Development Of The Rheumatoid Arthritis Drugs Market?

Major companies operating in the rheumatoid arthritis drugs market include Pfizer Inc., Abbvie Inc., Amgen Inc., Novartis AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, F-Hoffmann La Roche AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Merck & Co Inc., Johnson & Johnson Inc., Bayer AG, Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A, Biogen Inc., Regeneron Pharmaceuticals Inc., Galapagos NV, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, UCB S.A., Astellas Pharma Inc., Corbus Pharmaceuticals Holdings Inc., Roche Holding AG, Daiichi Sankyo Company Limited, Mallinckrodt Pharmaceuticals, Gilead Sciences Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report

What Are The Key Regional Developments Shaping The Rheumatoid Arthritis Drugs Market?

North America was the largest region in the rheumatoid arthritis drugs market in 2024.North America is expected to be the fastest-growing region in the global rheumatoid arthritis market report during the forecast period. The regions covered in the rheumatoid arthritis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10120&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model